Zimmer Biomet Holdings (ZBH) Stock Overview
Operates as a medical technology company worldwide. More details
| Snowflake Score | |
|---|---|
| Valuation | 5/6 |
| Future Growth | 1/6 |
| Past Performance | 1/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
ZBH Community Fair Values
Create NarrativeSee what 49 others think this stock is worth. Follow their fair value or set your own to get alerts.
Zimmer Biomet Holdings, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$91.40 |
| 52 Week High | US$108.29 |
| 52 Week Low | US$84.59 |
| Beta | 0.61 |
| 1 Month Change | -2.88% |
| 3 Month Change | -1.37% |
| 1 Year Change | -11.08% |
| 3 Year Change | -30.43% |
| 5 Year Change | -45.75% |
| Change since IPO | 207.12% |
Recent News & Updates
Recent updates
Zimmer Biomet: Down On Its Knees, Shares Look Appealing
Mar 23There May Be Some Bright Spots In Zimmer Biomet Holdings' (NYSE:ZBH) Earnings
Nov 14
Here's Why Zimmer Biomet Holdings (NYSE:ZBH) Can Manage Its Debt Responsibly
Jul 22Many Still Looking Away From Zimmer Biomet Holdings, Inc. (NYSE:ZBH)
Jul 04Zimmer Biomet Holdings (NYSE:ZBH) Is Paying Out A Dividend Of $0.24
Jun 16Zimmer Biomet Holdings' (NYSE:ZBH) Dividend Will Be $0.24
Jun 02Zimmer Biomet Holdings (NYSE:ZBH) Shareholders Will Want The ROCE Trajectory To Continue
May 27Some May Be Optimistic About Zimmer Biomet Holdings' (NYSE:ZBH) Earnings
May 12An Intrinsic Calculation For Zimmer Biomet Holdings, Inc. (NYSE:ZBH) Suggests It's 39% Undervalued
Apr 09Zimmer Biomet: Adding To The Growth Profile
Feb 07Zimmer Biomet: Back On Offense With Strong Cash Flow Outlook
Jan 05Shareholder Returns
| ZBH | US Medical Equipment | US Market | |
|---|---|---|---|
| 7D | 1.1% | -0.8% | 1.2% |
| 1Y | -11.1% | -6.9% | 32.8% |
Return vs Industry: ZBH underperformed the US Medical Equipment industry which returned -6.4% over the past year.
Return vs Market: ZBH underperformed the US Market which returned 31.9% over the past year.
Price Volatility
| ZBH volatility | |
|---|---|
| ZBH Average Weekly Movement | 3.3% |
| Medical Equipment Industry Average Movement | 7.9% |
| Market Average Movement | 7.1% |
| 10% most volatile stocks in US Market | 16.1% |
| 10% least volatile stocks in US Market | 3.3% |
Stable Share Price: ZBH has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: ZBH's weekly volatility (3%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1927 | 17,000 | Ivan Tornos | www.zimmerbiomet.com |
Zimmer Biomet Holdings, Inc., together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, upper extremities, and trauma and CMFT products; sports medicine products for the repair of soft tissue injuries, used in the knee and shoulder; and craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open-heart surgery, trauma, or for deformities of the chest. It offers technology and data, bone cement, and surgical products; and a suite of integrated digital and robotic technologies that leverage data, data analytics and artificial intelligence.
Zimmer Biomet Holdings, Inc. Fundamentals Summary
| ZBH fundamental statistics | |
|---|---|
| Market cap | US$17.61b |
| Earnings (TTM) | US$705.10m |
| Revenue (TTM) | US$8.23b |
Is ZBH overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ZBH income statement (TTM) | |
|---|---|
| Revenue | US$8.23b |
| Cost of Revenue | US$2.49b |
| Gross Profit | US$5.74b |
| Other Expenses | US$5.03b |
| Earnings | US$705.10m |
Last Reported Earnings
Dec 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | 3.64 |
| Gross Margin | 69.71% |
| Net Profit Margin | 8.57% |
| Debt/Equity Ratio | 60.1% |
How did ZBH perform over the long term?
See historical performance and comparisonDividends
Does ZBH pay a reliable dividends?
See ZBH dividend history and benchmarks| Zimmer Biomet Holdings dividend dates | |
|---|---|
| Ex Dividend Date | Mar 31 2026 |
| Dividend Pay Date | Apr 30 2026 |
| Days until Ex dividend | 8 days |
| Days until Dividend pay date | 22 days |
Does ZBH pay a reliable dividends?
See ZBH dividend history and benchmarksCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/04/07 04:27 |
| End of Day Share Price | 2026/04/07 00:00 |
| Earnings | 2025/12/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Zimmer Biomet Holdings, Inc. is covered by 47 analysts. 25 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| David Toung | Argus Research Company |
| Jeffrey Johnson | Baird |
| Adam Feinstein | Barclays |